



Principal Consultant

**Catia Twal**

email: [ctwal@edgewortheconomics.com](mailto:ctwal@edgewortheconomics.com)

### Washington, DC

1111 19th Street NW  
12th Floor  
Washington, DC 20036  
202.407.7152

### PRACTICE AREAS

Antitrust & Competition

Antitrust Litigation

Class Certification

Damages

Data Analytics

Discrimination

Labor & Employment

Pharmaceutical Economics

Transfer Pricing

### EDUCATION

Ms. Twal received her BS in economics, *summa cum laude*, from The College of New Jersey.

Catia Twal is experienced in building complex datasets and developing rigorous analyses for antitrust litigation involving assessment of class certification for direct and indirect purchasers, determining liability, and estimating damages in a variety of industries. Ms. Twal works most extensively in Edgeworth's pharmaceutical economics practice, where she prepares large databases for discovery, and conducts statistical testing and econometric modeling in matters including price fixing, monopolization, market allocation, and pay-for-delay. In her labor and employment work, Ms. Twal conducts analyses for litigation and mediation involving claims of discrimination in hiring, pay, and promotion.

In supporting expert testimony and in consulting engagements, Ms. Twal manages teams of consultants, and develops clear and intuitive methods of presenting analytical findings to attorneys and clients. Ms. Twal also has expertise in advanced data visualizations, using Tableau to create interactive dashboards to present findings.

### COMMUNITY & PROFESSIONAL

- American Bar Association Economic Ambassador
- American Bar Association Health Care and Pharmaceuticals Committee Member

### CASE HIGHLIGHTS

The Impact of the School-to-Prison Pipeline on Girls of Color in Massachusetts  
Edgeworth contributed to the efforts of Massachusetts Appleseed on a community-led examination of racial and gender-based disparities in schools.

## **EDGEWORTH INSIGHTS**

House Committee Launches Investigation of Pharmacy Benefit Managers (PBMs)

04.04.2023

## **THE ANTITRUST PRESCRIPTION**

FTC Challenges Amgen Acquisition of Horizon: More to Come Under Broadened Section 5

07.26.2023

Merck and Glenmark Settle on the Eve of a Rare Pay-For-Delay Trial

05.30.2023

## **NEWS**

Project Spotlight: School Discipline and Girls in Communities of Color

01.06.2022